Evotec stock
EVT.DEXETRAEvotec SE, HealthcareISIN DE0005664809WKN 566480
32Score 32 out of 100, Weak
Price and trend
50 / 100
Price history
−42% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 26% below it.
Since April 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 52% below its 52-week high. Largest decline in 20 years: 95% (September 2021 to October 2026).
Chart figures for advanced users
- SMA 50$3.20
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.69
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.70
- The lowest closing price of the last twelve months.
- Resistance$7.21
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Evotec SE belongs to the Drug Manufacturers (Specialty & Generic) industry (Germany) and, with a market value of $613.98M, is number 69 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $873.6M (down 1.1% year on year) and a loss of $114.71M.
- For fiscal 2026, analysts expect on average revenue of $667.85M (down 23.6%) and adjusted earnings per share of −$1.59.
Show more
- MEQIRI Score 32 out of 100 (Weak): rank 657 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $463.72M, financial debt $462.31M.Stability 50
Weaknesses
- Loss-makingLoss of $200.24M over the last 12 months.Fundamentals 29
- Turned to a lossEarnings per share from $0.04 in 2020 to −$0.64.Growth 37
- Negative free cash flowFree cash flow −$139.82M over the last 12 months.Fundamentals 29
The score is held back by capital allocation and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 5% on the twelve months before. Revenue has grown strongly since 2006, at around 14% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 8%, operating −18%, net −13%. Last 12 months: net −25%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 14 Apr 2027in 152 days
- Last reported
- 5 Nov 2026EPS reported −$0.17 (expected −$0.35)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 15.2% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$1.59−12.9%
- Revenue
- $667.85M+0.3%
- Earnings per share
- −$0.42−15.2%
- Revenue
- $778.68M−2.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −28.9%2026 guidance lowered: lower second-half revenue from strategic partnerships because of longer timelines for new agreements, plus continued softness in early drug discovery.
“We now expect lower than anticipated revenue contributions in the second half of 2026 as a result of longer timelines for reaching and finalizing new agreements.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 14 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Evotec
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 32
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Harrow HealthHROW $1.06B38
- PharmanutraPHN.MI $892.32M62
- Ironwood PharmaceuticalsIRWD $802.92M72
- Collegium PharmaceuticalCOLL $775.33M51
- Alpha TeknovaTKNO $522.1M44
- EvolusEOLS $475.23M44
- KamadaKMDA $468.95M66
- Aquestive TherapeuticsAQST $448.71M29
ETFs that hold Evotec
Held by 20 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi SDAX UCITS ETF DistC005 | 1.21% | 0.70% | €158.8M |
| iShares TecDAX UCITS ETF (DE)EXS2 | 0.39% | 0.51% | €12.44M |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.15% | 0.40% | €580.62M |
Show 5 more
| iShares MSCI EMU Small Cap UCITS ETFSXRJ | 0.08% | 0.58% | €838.19M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.06% | 0.23% | €321.86M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.05% | 0.40% | €1.5B |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.03% | 0.30% | €3.45B |
| Vanguard Germany All Cap UCITS ETF (EUR) DistributingVGER | 0.03% | 0.07% | €255.26M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2023)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.